IN2014MN02367A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02367A IN2014MN02367A IN2367MUN2014A IN2014MN02367A IN 2014MN02367 A IN2014MN02367 A IN 2014MN02367A IN 2367MUN2014 A IN2367MUN2014 A IN 2367MUN2014A IN 2014MN02367 A IN2014MN02367 A IN 2014MN02367A
- Authority
- IN
- India
- Prior art keywords
- blys
- stimulating factor
- blys antibody
- lymphocyte stimulating
- biopharmaceutics
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210160474.3A CN103421113B (zh) | 2012-05-22 | 2012-05-22 | 抗BLyS抗体 |
| PCT/CN2013/076074 WO2013174264A1 (zh) | 2012-05-22 | 2013-05-22 | 抗BLyS抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02367A true IN2014MN02367A (cg-RX-API-DMAC10.html) | 2015-08-14 |
Family
ID=49623127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2367MUN2014 IN2014MN02367A (cg-RX-API-DMAC10.html) | 2012-05-22 | 2013-05-22 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9828423B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP2853543B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6006404B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN103421113B (cg-RX-API-DMAC10.html) |
| IN (1) | IN2014MN02367A (cg-RX-API-DMAC10.html) |
| RU (1) | RU2613422C2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2013174264A1 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA201408955B (cg-RX-API-DMAC10.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0615672D0 (en) | 2006-08-07 | 2006-09-13 | Rencol Tolerance Rings Ltd | Assembly of a shaft and a housing assembly |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| CN104045713B (zh) * | 2013-03-13 | 2019-02-12 | 江苏诺迈博生物医药科技有限公司 | 一种抗Blys的单克隆抗体及含有该抗体的药物组合物 |
| CN104804092B (zh) * | 2014-01-29 | 2018-03-27 | 天津胜发生物技术有限公司 | 一种抗b细胞生长刺激因子的纳米抗体及其用途 |
| CN104804091B (zh) * | 2014-01-29 | 2018-03-27 | 普瑞金（深圳）生物技术有限公司 | 一种抗b细胞生长刺激因子的纳米抗体及用途 |
| CN104804090B (zh) * | 2014-01-29 | 2018-03-27 | 普瑞金（深圳）生物技术有限公司 | 一种抗b细胞生长刺激因子的纳米抗体和用途 |
| US20170101466A1 (en) * | 2014-06-03 | 2017-04-13 | Masahisa Handa | Anti-blys antibodies |
| CN104628856A (zh) * | 2015-01-23 | 2015-05-20 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种抗BLyS单链抗体及其制备方法和用途 |
| CN105061596B (zh) * | 2015-08-05 | 2019-01-29 | 江苏诺迈博生物医药科技有限公司 | 人b淋巴细胞刺激因子的单克隆抗体及其应用 |
| CN106916224B (zh) * | 2015-12-28 | 2021-03-23 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 抗b淋巴细胞刺激因子单克隆抗体及其制备方法和用途 |
| KR20230047507A (ko) | 2016-06-27 | 2023-04-07 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
| JP2019533423A (ja) * | 2016-07-06 | 2019-11-21 | シャンハイ ファーマエクスプローラー カンパニー，リミティド | ＢＬｙＳ抗体及びその製造方法と応用 |
| JP7325045B2 (ja) * | 2017-02-27 | 2023-08-14 | カイロス セラピューティクス， インコーポレイテッド | 癌を処置する抗体コンストラクトおよび方法 |
| WO2020160199A1 (en) * | 2019-01-31 | 2020-08-06 | Siemens Healthcare Diagnostics Inc. | Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof |
| CN112111461B (zh) * | 2020-08-17 | 2022-08-30 | 浙江正熙生物医药有限公司 | 一种单细胞分选构建单克隆抗体高产株细胞工作库的方法 |
| WO2022223028A1 (zh) * | 2021-04-23 | 2022-10-27 | 上海君实生物医药科技股份有限公司 | 抗BLyS抗体、其药物组合物及其用途 |
| US20240182599A1 (en) * | 2022-10-07 | 2024-06-06 | Abwiz Bio, Inc. | Anti-ige antibodies |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6812327B1 (en) * | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| NZ334309A (en) * | 1996-10-25 | 2000-08-25 | Human Genome Sciences Inc | Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| WO2003055979A2 (en) * | 2001-11-16 | 2003-07-10 | Human Genome Sciences, Inc. | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS |
| US20020150579A1 (en) * | 2002-01-10 | 2002-10-17 | Kimberly Robert P. | B lymphocyte stimulator (BLyS) as a marker in management of systemic lupus erythematosus |
| CN1168831C (zh) | 2002-05-24 | 2004-09-29 | 张志方 | 一种重组人b淋巴细胞刺激因子表达载体的构建、dna免疫制备单克隆抗体及其应用 |
| RU2005141541A (ru) * | 2003-06-05 | 2006-06-27 | Дженентек, Инк. (Us) | Комбинированная терапия в-клеточных нарушений |
| WO2005042009A1 (en) * | 2003-10-20 | 2005-05-12 | Biogen Idec Ma Inc. | Therapeutic regimens for baff antagonists |
| CN101851291B (zh) * | 2010-02-09 | 2011-10-26 | 中国人民解放军第四军医大学 | 一种抗人baff单克隆抗体的重链和轻链可变区 |
-
2012
- 2012-05-22 CN CN201210160474.3A patent/CN103421113B/zh active Active
-
2013
- 2013-05-22 US US14/401,288 patent/US9828423B2/en active Active
- 2013-05-22 WO PCT/CN2013/076074 patent/WO2013174264A1/zh not_active Ceased
- 2013-05-22 IN IN2367MUN2014 patent/IN2014MN02367A/en unknown
- 2013-05-22 RU RU2014133410A patent/RU2613422C2/ru active
- 2013-05-22 EP EP13794561.4A patent/EP2853543B1/en active Active
- 2013-05-22 EP EP20180342.6A patent/EP3792280A3/en not_active Withdrawn
- 2013-05-22 JP JP2015511926A patent/JP6006404B2/ja active Active
-
2014
- 2014-12-05 ZA ZA2014/08955A patent/ZA201408955B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014025651A2 (pt) | 2017-07-04 |
| WO2013174264A1 (zh) | 2013-11-28 |
| EP3792280A3 (en) | 2021-07-21 |
| EP3792280A2 (en) | 2021-03-17 |
| EP2853543A8 (en) | 2015-05-13 |
| RU2613422C2 (ru) | 2017-03-16 |
| ZA201408955B (en) | 2015-12-23 |
| EP2853543B1 (en) | 2020-09-02 |
| JP2015517505A (ja) | 2015-06-22 |
| EP2853543A1 (en) | 2015-04-01 |
| US9828423B2 (en) | 2017-11-28 |
| CN103421113B (zh) | 2018-01-19 |
| JP6006404B2 (ja) | 2016-10-12 |
| CN103421113A (zh) | 2013-12-04 |
| EP2853543A4 (en) | 2016-03-30 |
| RU2014133410A (ru) | 2016-07-10 |
| US20150259409A1 (en) | 2015-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3792280A3 (en) | Anti-blys antibody | |
| AU2018253544A1 (en) | Methods for treating or preventing asthma by administering an IL-4R antagonist | |
| WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
| MX389160B (es) | Células no t efectoras y madre/progenitoras hematopoyéticas modificadas y usos de estas. | |
| EA201591740A1 (ru) | Вирусы болезни ньюкасла и их применение | |
| BR112014026952A2 (pt) | derivados de aminopirimidina pirazol como moduladores lrrk2 | |
| IN2014MN01642A (cg-RX-API-DMAC10.html) | ||
| MX2022009538A (es) | Nanoportadores sinteticos tolerogenicos y macromoleculas terapeuticas para efectos farmacodinamicos reducidos o intensificados. | |
| UA117072C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським | |
| MX380555B (es) | Combinación de anticuerpos anti-gen 3 de la activación de linfocito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores. | |
| MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
| NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| EA201690618A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| BR112015031903A8 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto | |
| MY191358A (en) | Triazolopyrazines as brd4 inhibitors for use in the treatment of cancer | |
| EA201270815A1 (ru) | Модуляторы рецепторов эстрогена и их применение | |
| MX357496B (es) | Moduladores del receptor de estrógenos fluorados y sus usos. | |
| EP3016715A4 (en) | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy | |
| MX2015009058A (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| ME03078B (me) | Derivati sulfonil piperidina i njihova upotreba za lečenje bolesti posredovanih preko prokineтicina | |
| EA201491613A1 (ru) | Катионные полимеры на основе гликогена | |
| MY182222A (en) | Pharmaceutical compositions and methods of use of 4-pregenen- 11?-17-21-triol-3,20-dione derivatives | |
| MX365403B (es) | Peptidos y metodos para usarlos. | |
| EA201591196A1 (ru) | Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств |